Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes
The video series, Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes, provides expert insights on patient selection, treatment sequencing, and managing adverse events to improve care for EGFR+ and ALK+ metastatic NSCLC patients.
EP. 1: Robert’s Journey With EGFR+ Metastatic NSCLC
The video segment profiles a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.
EP. 2: The Impact of Molecular Testing on Treatment Choices for NSCLC
A discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.
EP. 3: Overview of FLAURA and MARIPOSA-2 Clinical Trials
Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.
EP. 4: Clinical Experience of Amivantamab in EGFR+ NSCLC Patients
Dr. Kim shares his clinical experience with amivantamab in real-world practice for EGFR+ NSCLC, discussing both the benefits and challenges of incorporating it into treatment protocols.
EP. 6: Evaluating Treatment Options of EGFR Inhibitors
Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.
EP. 9: Barriers and Challenges in Biomarker Testing for ALK+ NSCLC
Dr. Garon discusses the factors that make a patient a strong candidate for ALK inhibitor therapy in ALK+ NSCLC, the importance of biomarker testing in guiding treatment selection, and his approach to testing along with challenges encountered, especially in community settings.
EP. 10: Overview of Efficacy of Lorlatinib in the Treatment of ALK+ NSCLC
Dr. Kim provides an overview of the clinical evidence supporting lorlatinib as a first-line therapy for ALK+ metastatic NSCLC, focusing on the key efficacy outcomes from the phase 3 CROWN trial.
EP. 11: Overview of Current Treatment Landscape of ALK Inhibitors
Dr. Garon describes the current treatment landscape for metastatic ALK+ NSCLC and explores alternative treatment options that could have been considered for these patients.
EP. 12: Clinical Experience of Lorlatinib ALK+ NSCLC Patients
Dr. Kim discusses her experience with lorlatinib in real-world settings for ALK+ NSCLC, highlighting both the benefits and challenges of incorporating it into clinical practice.
